Market Overview

UPDATE: Canaccord Genuity Raises HeartWare International's PT

Related HTWR
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise

According to a research report published this morning, Canaccord Genuity has increased HeartWare International's (NASDAQ: HTWR) PT from $95 to $101.

In the report, Canaccord Genuity commented, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."

Canaccord Genuity maintains its Buy rating on HeartWare International, which closed yesterday at $77.14.

Latest Ratings for HTWR

DateFirmActionFromTo
Aug 2014JP MorganMaintainsOverweight
May 2014OppenheimerMaintainsOutperform
Apr 2014Goldman SachsDowngradesNeutralSell

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (HTWR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters